did-ac-immune's-(nasdaq:aciu)-share-price-deserve-to-gain-34%?

Did AC Immune's (NASDAQ:ACIU) Share Price Deserve to Gain 34%?

NASDAQ:ACIU) share price is 34% higher than it was a year ago, much better than the market return of around 17% (not including dividends) in the same period. That’s a solid performance by our standards! In contrast, the longer term returns are negative, since the share price is 4.0% lower than it was three years ago.” data-reactid=”28″ type=”text”>The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. To wit, the AC Immune SA (NASDAQ:ACIU) share price is 34% higher than it was a year ago, much better than the market return of around 17% (not including dividends) in the same period. That’s a solid performance by our standards! In contrast, the longer term returns are negative, since the share price is 4.0% lower than it was three years ago.

See our latest analysis for AC Immune ” data-reactid=”29″ type=”text”> See our latest analysis for AC Immune

Because AC Immune made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

AC Immune actually shrunk its revenue over the last year, with a reduction of 40%. Despite the lack of revenue growth, the stock has returned a solid 34% the last twelve months. To us that means that there isn’t a lot of correlation between the past revenue performance and the share price, but a closer look at analyst forecasts and the bottom line may well explain a lot.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth

balance sheet strength is a great place to start, if you want to investigate the stock further.” data-reactid=”49″ type=”text”>This free interactive report on AC Immune’s balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

3 warning signs for AC Immune (1 can’t be ignored) that you should be aware of.” data-reactid=”51″ type=”text”>Pleasingly, AC Immune’s total shareholder return last year was 34%. What is absolutely clear is that is far preferable to the dismal 1.3% average annual loss suffered over the last three years. It could well be that the business has turned around — or else regained the confidence of investors. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we’ve identified 3 warning signs for AC Immune (1 can’t be ignored) that you should be aware of.

list of companies. (Hint: insiders have been buying them).” data-reactid=”52″ type=”text”>If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”54″ type=”text”>

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top